The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Synonym:||anti-TRAIL receptor 2 monoclonal antibody AMG 655|
|Code name:||AMG 655|
|Chemical structures:||immunoglobulin G1, anti-(human cytokine receptor DR5 (death receptor 5)) (human monoclonal XG1-048 v w heavy chain), disulfide with human monoclonal XG1-048 v w light chain, dimer |
immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10B (death receptor 5, TRAIL-R2, CD262 antigen)); human monoclonal XG1-048 [Arg219,Glu361,Met363]γ1 heavy chain (225-215')-disulfide with κ light chain (231- 231'':234-234'')-bisdisulfide dimer